This Week in Rheumatology — Jun 6, 2026

Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning new therapeutic breakthroughs in systemic diseases like lupus and polymyalgia rheumatica, a refinement of our approach to common conditions like osteoarthritis, and a look at the future of rheumatology through the lenses of precision medicine and health equity. Let's dive in.

This week saw a wealth of positive trial data for challenging systemic inflammatory diseases, with a strong focus on effective, glucocorticoid-sparing strategies. Kicking things off are two major trials from The New England Journal of Medicine. First, for polymyalgia rheumatica, a phase 3 trial evaluated the interleukin-17A inhibitor secukinumab in patients who had recently relapsed [2]. Investigators enrolled 381 patients and randomized them to receive either secukinumab at 300 milligrams, 150 milligrams, or placebo for 52 weeks. Critically, all patients also received prednisone on a standardized 24-week tapering schedule. The primary outcome was sustained remission at week 52. The results were quite clear: sustained remission was achieved in about 41% of patients in both secukinumab groups, compared to just 20% in the placebo group—a statistically significant difference that effectively doubled the rate of sustained response. As a key secondary outcome, the treatment also led to lower cumulative glucocorticoid doses over the year. The mean adjusted annual dose was around 1600 to 1700 milligrams in the secukinumab arms, versus nearly 2100 milligrams with placebo. While adverse events like nasopharyngitis and infections were more common with secukinumab, the rate of serious adverse events was similar across all groups. This trial provides strong evidence for a new, effective option for our patients with relapsed PMR, potentially changing the standard of care. Also in The New England Journal of Medicine, we have a phase 3 trial of obexelimab for IgG4-related disease [3]. Obexelimab is a novel bifunctional monoclonal antibody that inhibits B-cell activity by engaging both CD19 and Fc-gamma-R-two-b, but it does so without causing B-cell depletion. In this trial, 194 patients with active disease were randomized to weekly subcutaneous obexelimab or placebo for 52 weeks, with a standardized glucocorticoid taper to discontinuation at week 8 in both groups. The primary endpoint was the time to the first disease flare requiring rescue therapy. The study found that the time to flare was significantly longer with obexelimab, with a hazard ratio of 0.44. In concrete terms, flares occurred in only about 27% of patients on obexelimab, compared to nearly 55% of those on placebo. Furthermore, obexelimab was superior on all key secondary endpoints, including achieving complete remission at week 52—seen in 37% of the treatment group versus 20% of the placebo group—and a substantially lower cumulative dose of rescue glucocorticoids. Serious adverse events were actually less common in the obexelimab group. This is a significant advance for a condition where we have long relied on glucocorticoids. Shifting to systemic lupus erythematosus, The Lancet published the PHOENYCS GO phase 3 trial of dapirolizumab pegol, a novel CD40 ligand inhibitor [9]. In this study, 321 patients with moderate-to-severe, active SLE on standard-of-care medications were randomized 2-to-1 to receive intravenous dapirolizumab or placebo every four weeks. The primary outcome was a BICLA response at week 48. The trial met its primary endpoint, with a significantly greater proportion of patients on dapirolizumab achieving a BICLA response—50% versus 35% in the placebo group. This represents a 15-point absolute difference. The safety profile was manageable, with serious adverse events occurring in 10% of the dapirolizumab group compared to 15% of the placebo group. These findings support the further investigation of dapirolizumab as a new treatment option for SLE. For patients with progressive systemic sclerosis, a study in Arthritis & Rheumatology offers an early but promising look at CD19 CAR-T cell therapy [7]. Patients received the therapy, known as relma-cel, and were followed longitudinally. The treatment was associated with a manageable safety profile and induced rapid B-cell depletion followed by immune reconstitution. Clinically, patients showed sustained improvement across multiple disease domains, including skin involvement and both patient- and physician-reported disease activity. To understand the underlying biology, the researchers performed longitudinal proteomic profiling. This revealed broad remodeling of inflammatory and fibrotic pathways, with downregulation of profibrotic proteins and upregulation of proteins associated with vascular repair. While this study is small, the combination of clinical improvement and supportive molecular data is highly encouraging and warrants larger trials for this difficult-to-treat condition. Finally, in the realm of nephro-rheumatology, a paper in JAMA provides important data on finerenone for patients with glomerular diseases [1]. This was a prespecified exploratory subgroup analysis of a larger trial, focusing on 903 participants with investigator-reported glomerular disease, including IgA nephropathy and focal segmental glomerulosclerosis. These patients were randomized to the nonsteroidal mineralocorticoid receptor antagonist finerenone or placebo. The analysis showed that finerenone significantly slowed the rate of eGFR decline by about 0.73 mL/min/1.73 m2 per year compared to placebo. It also reduced albuminuria by 42% at 12 months and lowered the risk of a composite outcome of kidney failure or a sustained 40% eGFR decline. These findings suggest an important role for finerenone in preserving kidney function in this specific population.

Beyond new drugs, several papers this week encourage us to refine our fundamental approaches to diagnosis and disease classification. A practical narrative review in Osteoarthritis and Cartilage reminds us of the fundamentals of diagnosing osteoarthritis [6]. The authors emphasize that despite its high prevalence, OA is often underdiagnosed. They stress that OA is primarily a clinical diagnosis, integrating patient symptoms and physical examination findings. Radiographs and other investigations rarely alter the diagnosis or management when typical clinical features are present, and importantly, normal radiographs do not exclude early-stage disease. Imaging should be reserved for cases with diagnostic uncertainty. The review advocates for a comprehensive, holistic assessment that addresses not only joint symptoms but also the impact on work and social participation, considering the full biopsychosocial context. This 'back-to-basics' clinical approach is echoed in a review from The Lancet Rheumatology on managing non-specific low back pain in primary care [10]. This paper summarizes recommendations from international clinical practice guidelines published over the last 30 years. The consistent message is that for the vast majority of patients, low back pain is non-specific, and management should focus on evidence-based primary care strategies like patient education and staying active, while de-emphasizing routine imaging and specialist referral. Moving from the bedside to the bench, a study in Annals of the Rheumatic Diseases offers a new way to conceptualize the connections between our major systemic autoimmune diseases [8]. Researchers performed integrated transcriptomic and epigenomic profiling on over 260 treatment-naive patients with rheumatoid arthritis, systemic lupus erythematosus, and primary Sjögren's syndrome. Their analysis uncovered two robust and reproducible molecular subtypes that were conserved across all three diseases: a 'megakaryocyte-enriched' subtype and a 'B-cell-enriched' subtype. These subtypes had distinct clinical correlations; the megakaryocyte-enriched subtype was associated with higher platelet counts, greater disease activity, and broader organ involvement. Epigenomic mapping confirmed that these subtypes had different regulatory architectures, with distinct super-enhancers driving genes like ZFP36L1 in the megakaryocyte group and PRDM1 in the B-cell group. This cross-disease taxonomy may inform future precision stratification and the development of lineage-targeted therapies.

Finally, two papers look to the future, one addressing how we generate evidence and the other highlighting the urgent need for health equity. First, for anyone involved in creating guidelines or systematic reviews, a report in Annals of the Rheumatic Diseases evaluates the use of machine learning tools to assist in the process [5]. The authors replicated the manual title and abstract screening for four systematic literature reviews that informed the 2025 update of the EULAR rheumatoid arthritis management recommendations. Using three different machine learning tools, they found that they could achieve a substantial workload reduction, screening on average 78% fewer abstracts, while still consistently capturing over 95% of all relevant records. This demonstrates the considerable potential of these tools to support and accelerate future evidence synthesis while maintaining high methodological standards. And on a critical policy note, a viewpoint article, also from Annals of the Rheumatic Diseases, issues an urgent call to prioritize women's health in rheumatology [4]. The authors highlight the significant sex- and gender-based disparities in our field. Many common RMDs, including osteoarthritis, rheumatoid arthritis, SLE, and fibromyalgia, have a higher prevalence and greater burden in women. Women frequently experience prolonged diagnostic delays, receive incorrect initial diagnoses, and face unequal access to effective treatments. The authors argue these inequities are compounded by biases in medical education and research, where women's symptoms are often dismissed. They advocate for the urgent inclusion of RMDs within the growing Women's Health agenda to drive targeted research and implement gender-sensitive strategies.

If you only have time for one paper this week, make it the phase 3 trial of secukinumab for polymyalgia rheumatica in The New England Journal of Medicine [2]. It provides high-quality evidence for a new, effective glucocorticoid-sparing option in a common and challenging condition, which could change the standard of care for relapsed PMR.

Here are the key takeaways from this week in Rheumatology. In relapsed polymyalgia rheumatica, secukinumab significantly increases rates of sustained remission and reduces cumulative glucocorticoid exposure, offering a new potential standard of care [2]. For our patients with IgG4-related disease and systemic lupus erythematosus, two new biologics—obexelimab and dapirolizumab, respectively—have shown significant efficacy in phase 3 trials, reducing flares and disease activity [3, 9]. Don't forget the kidneys: In patients with chronic kidney disease from glomerular diseases like IgA nephropathy, finerenone slows the rate of eGFR decline and reduces albuminuria, providing a new tool to preserve renal function [1]. Remember the fundamentals for common conditions: Osteoarthritis and non-specific low back pain remain primarily clinical diagnoses where imaging should be used judiciously, and a holistic patient assessment is paramount [6, 10]. Finally, a new molecular taxonomy is emerging that cuts across RA, SLE, and Sjögren's, identifying shared 'megakaryocyte-enriched' and 'B-cell-enriched' subtypes that correlate with disease severity and may guide future targeted therapies [8].

That's your roundup for This Week in Rheumatology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.